This competing renewal application is focused on functional proteomics studies of activated protein C (APC), an enzyme that exerts two major, distinct activities - (1) anticoagulant activity by targeting coagulation factors Va and Vllla in reactions requiring APC cofactors and (2) direct anti-apoptotic and anti-inflammatory effects on cells by targeting two APC receptors, protease activated receptor 1 (PAR1) and Endothelial Protein C Receptor (EPCR). Our published work and unpublished preliminary data lead directly to the proposed studies and provide strong support for our hypotheses. We hypothesize that EPCR-dependent effects of APC on cells derive, at least in part, from APC's cleavage at Arg41 in PAR1 in a reaction involving PAR1-specific exosites on APC that differ from factor Va exosites. We hypothesize that PAR1 on cells interacts directly with EPCR via extracellular protein loops and/or via transmembrane helix-helix interactions. We hypothesize that there are additional cofactors or adaptors that influence APC's direct effects on cells. We hypothesize that APC endocytosis is required for APC's anti-apoptotic activity and that endocytosed APC directly exerts intracellular anti-apoptotic activity in cells. We hypothesize that APC exerts antiapoptotic activity by downregulating caspase 3 generation and that APC might act upstream of mitochondrial release of cyt c. In testing these hypotheses, we propose: 1) to expand the mutational framework for understanding APC's enzymatic targeting of its key substrates, 2) to characterize high density lipoprotein (HDL) and factor V as APC cofactors, 3) to clarify mechanisms responsible for APC's direct effects on endothelial cells, and 4) to evaluate APC's novel intracellular anti-apoptotic activity. In related translational research, we propose to assess relationships between thrombotic disease and the APC receptors, PAR1 and EPCR, and between thrombotic disease and plasma levels of the APC lipid cofactor, glucosylceramide. These studies will improve our ability to understand, diagnose and treat thrombotic diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL052246-14
Application #
7331503
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Link, Rebecca P
Project Start
2004-12-27
Project End
2009-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
14
Fiscal Year
2008
Total Cost
$696,246
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Gupta, Naveen; Liu, Roland; Shin, Stephanie et al. (2018) SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. J Antimicrob Chemother 73:1586-1594
Prince, Raja; Bologna, Luca; Manetti, Mirko et al. (2018) Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood 131:1360-1371
Gupta, Naveen; Sinha, Ranjeet; Krasnodembskaya, Anna et al. (2018) The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. Stem Cells 36:796-806
Amar, Arun Paul; Sagare, Abhay P; Zhao, Zhen et al. (2018) Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. Neuropharmacology 134:293-301
Healy, Laura D; Rigg, Rachel A; Griffin, John H et al. (2018) Regulation of immune cell signaling by activated protein C. J Leukoc Biol :
Griffin, John H; Zlokovic, Berislav V; Mosnier, Laurent O (2018) Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132:159-169
Sinha, Ranjeet K; Wang, Yaoming; Zhao, Zhen et al. (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131:1163-1171
Martos, Laura; Ramón, Luis Andrés; Oto, Julia et al. (2018) ?2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:?2M Levels Are Associated with Venous Thromboembolism. Thromb Haemost 118:630-638
Deguchi, Hiroshi; Elias, Darlene J; Griffin, John H (2017) Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. Res Pract Thromb Haemost 1:93-102
Healy, Laura D; Puy, Cristina; Fernández, José A et al. (2017) Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. J Biol Chem 292:8616-8629

Showing the most recent 10 out of 70 publications